Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model

Blood

Volumn 105, Issue 9, 2005, Pages 3707-3713

  Kawakami, Mariko ^a   Kawakami, Koji ^a   Kioi, Mitomu ^a   Leland, Pamela ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; CYTOTOXIN; INTERLEUKIN 4; INTERLEUKIN 4 CYTOTOXIN; INTERLEUKIN 4 RECEPTOR; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; HODGKIN DISEASE; IMMUNOCOMPETENT CELL; LYMPH NODE METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; SURVIVAL;

EID: 18244408543     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3216     Document Type: Article

References (38)

1. Hsu SM, Waldron JW, Hsu PL, Hough AJ Jr. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol. 1993;24:1040-1057.
2. Klein S, Jucker M, Diehl V, Tesch H. Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol. 1992;10:319-329.
3. Gruss HJ, Brach MA, Drexter HG, Bonifer R, Mertelsmann RH, Herrmann F. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992;52:3353-3360.
4. Bargou RC, Mapara MY, Zugck C, et al. Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. J Exp Med. 1993;177:1257-1268.
5. Aldinucci D, Poletto D, Gloghini A, et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol. 2002;160:585-596.
6. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189:1939-1946.
7. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250-255.
8. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.
9. Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer. 2002;98:567-572.
10. Jundt F, Anagnostopoulos I, Bommert K, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells an eosinophils. Blood. 1999;94:2065-2071.
11. Küppers R, Rajewsky K. The origin of Hodgkin and Reed-Sternberg cells in Hodgkin disease. Annu Rev Immunol. 1998;16:471-493.
12. Glossmann JP, Josting A, Diehl V. New treatments for Hodgkin's disease. Curr Treat Options Oncol. 2002;3:283-290.
13. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95:3909-3914.
14. Barth S, Huhn M, Matthey B, et al. Recombinant anti-CD25 immunotoxin RFT(ScFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer. 2000;86:718-724.
15. Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease. Int J Mol Med. 2000;6:509-514.
16. Arndt MAE, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors. Blood. 1999;94:2562-2568.
17. Schnell R, Staak O, Borchmann P, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refrectory CD30+ Hodgkin's an non Hodgkin's lymphoma. Clin Cancer Res. 2002;8:1779-1786.
18. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100:3101-3107.
19. Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med. 1999;5:817-822.
20. Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002;62:3575-3580.
21. Kawakami M, Kawakami K, Stepensky VA, et al. Interleukin-4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res. 2002;8:3503-3511.
22. Kawakami M, Kawakami K, Puri RK. Interleukin-4 Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neuro-Oncol. 2003;65:15-25.
23. Puri RK. Structure and function of interleukin-4 and its receptor. In: Kurzrock R, Talpaz M, eds. Cytokines: Interleukins and Their Receptors. Norwell, MA: Kluwer Academic Publishers; 1995:143-185.
24. Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int J Mol Med. 1998;1:551-557.
25. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common γ chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995;270:8797-8804.
26. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300:1527-1528.
27. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA. 1994;91:6889-6893.
28. von Kalle C, Wolf J, Becker A, et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer. 1992;52:887-891.
29. Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol. 2001;211:37-42.
30. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194-6200.
31. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor α' but not α chain: a functional component of interleukin-4 receptors. Blood. 1998;91:3884-3891.
32. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4 Pseudomonas exotoxin chimeric protein. Int J Cancer. 1994;58:574-581.
33. So E-Y, Kim S-H, Park H-H, Cho B-S, Lee C-E. Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity. FEBS Lett. 2002;518:53-59.
34. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 2001;21:299-310.
35. Wolf J, Kapp U, Kornacker M, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood. 1996;87:3418-3428.
36. Morrison BW, Leder P. A receptor binding domain of mouse interleukin-4 defined by a solid phase binding assay and in vitro mutagenesis. J Biol Chem. 1992;267:11957-11963.
37. Newcom SR, Ansari AA, Gu L. Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell. Blood. 1992;79:191-197.
38. Trieu Y, Wen X-Y, Skinnider BF, et al. Soluble interleukin-13Rα2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res. 2004;64:3271-3275.